Page 6,424«..1020..6,4236,4246,4256,426..6,4306,440..»

Stem Cell Therapy—Breakthrough in Health Paradigm

Posted: Published on September 26th, 2012

By Sharmistha Banerjee - September 25, 2012 | Tickers: NBS, OSIR, PSTI | 0 Comments Sharmistha is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. Far-reaching accomplishments in the biotechnology sector meet its most ambitious expectations, stem cell therapy. The birth of this new industry has boosted the enthusiasm and energy of investors and has brought unprecedented capability and optimistic predictions. New developments in regenerative medicine are bringing about exciting, novel approaches to create therapies for hard to treat diseases. The biotechnology industry has been soaring in 2012 as companies both large and small have shown impressive growth. The cell therapy space has seen relatively small companies making strides in the right direction with increased government support. Osiris Therapeutics (NASDAQ: OSIR) a leading stem cell company is currently the only company with an approved cell therapy. The approval is more of a first step in a long walk for Osiris. Reuters reported that shares of Osiris Therapeutics rose 15% on May 30, 2012, after U.S. health regulators said the stem cell technology company's wound treatment was eligible for reimbursement when used in hospitals in out-patient settings … Continue reading

Comments Off on Stem Cell Therapy—Breakthrough in Health Paradigm

Pacemaker from Stem Cells Receives Research Funding

Posted: Published on September 26th, 2012

(SACRAMENTO, Calif.) - Deborah K. Lieu, a stem cell scientist in cardiovascular medicine at UC Davis Health System, has received a $1.3 million research grant from the California Institute for Regenerative Medicine (CIRM) to develop stem cells that could serve as a biological alternative to the electronic pacemakers that people now use to regulate heart rhythm. According to Lieu, each year 350,000 cardiology patients with abnormal heart rhythms receive electronic pacemakers to maintain a normal heart beat. The devices, while effective, have several disadvantages, including limited battery life and poor response to changing heart rates, such as when a person is exercising. Lieu, who is working with colleague Nipavan Chiamvimonvat, the Roger Tatarian Endowed Professor of Cardiovascular Medicine at UC Davis, plans to examine ways to improve the generation of pacemaking cells using human-induced pluripotent stem cells (hiPSCs), potentially creating what she calls a "biopacemaker." "There are more than 3 million patients around the country who are dependent on electronic pacemakers," said Lieu. "Each one costs about $58,000 to implant and requires follow-up surgery about every 5 to 10 years to change batteries. Creating a biopacemaker from stem cells would avoid the burden of battery replacement and provide the physiological … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Pacemaker from Stem Cells Receives Research Funding

Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant …

Posted: Published on September 26th, 2012

CAMBRIDGE, Mass. & BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the completion of patient enrollment in a phase III clinical trial of ADCETRIS (brentuximab vedotin) for post-transplant Hodgkin lymphoma (HL) patients. The phase III trial, also known as the AETHERA trial, is evaluating ADCETRIS versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL. We are pleased to complete the enrollment of this important phase III trial, evaluating the use of ADCETRIS for Hodgkin lymphoma patients who are at high risk of residual disease following an ASCT, said Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics. The AETHERA trial is designed to provide the medical community with valuable insight into the potential for ADCETRIS to consolidate responses in Hodgkin lymphoma patients following a transplant, and will be the first data on the use of ADCETRIS in a maintenance-type setting. We anticipate data from this trial will be available in late 2013 or early 2014. … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant …

Pacemaker from Stem Cells Receives Research Funding

Posted: Published on September 26th, 2012

(SACRAMENTO, Calif.) - Deborah K. Lieu, a stem cell scientist in cardiovascular medicine at UC Davis Health System, has received a $1.3 million research grant from the California Institute for Regenerative Medicine (CIRM) to develop stem cells that could serve as a biological alternative to the electronic pacemakers that people now use to regulate heart rhythm. According to Lieu, each year 350,000 cardiology patients with abnormal heart rhythms receive electronic pacemakers to maintain a normal heart beat. The devices, while effective, have several disadvantages, including limited battery life and poor response to changing heart rates, such as when a person is exercising. Lieu, who is working with colleague Nipavan Chiamvimonvat, the Roger Tatarian Endowed Professor of Cardiovascular Medicine at UC Davis, plans to examine ways to improve the generation of pacemaking cells using human-induced pluripotent stem cells (hiPSCs), potentially creating what she calls a "biopacemaker." "There are more than 3 million patients around the country who are dependent on electronic pacemakers," said Lieu. "Each one costs about $58,000 to implant and requires follow-up surgery about every 5 to 10 years to change batteries. Creating a biopacemaker from stem cells would avoid the burden of battery replacement and provide the physiological … Continue reading

Comments Off on Pacemaker from Stem Cells Receives Research Funding

BioRestorative Therapies Announces the Appointment of Harvard Medical School's Wayne Marasco, M.D., Ph.D., as Chairman …

Posted: Published on September 26th, 2012

JUPITER, Fla., Sept. 25, 2012 /PRNewswire/ --BioRestorative Therapies, Inc. ("BRT" or the "Company") (BRTX), a life sciences company focused on stem cell based cellular therapies for various personal medical applications, announced today that Wayne A. Marasco, M.D., Ph.D. has been appointed as Chairman of the Company's Scientific Advisory Board. Dr. Marasco currently serves as an Associate Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute. He is head of the Marasco Labs, an accomplished research laboratory at Dana-Farber Cancer Institute known for discovery and therapeutic human monoclonal antibody development and for constructing and validating various Human-Mouse chimeric models in the area of cancer, infectious disease immunotherapy, regenerative medicine and tissue engineering. Dr. Marasco is an Affiliated Faculty Member of the Harvard Stem Cell Institute and has extensive experience in the field of stem cells. In 2003, Dr. Marasco founded the National Foundation of Cancer Research Center for Therapeutic Antibody Engineering to expand the use of human monoclonal antibodies in the treatment of cancer. In 2009, he was listed among 13 top scientists in their field as the 21st century medicine "Pioneers of Medicine Progress" by US News & World Report. Dr. Marasco's recent work in the field of … Continue reading

Comments Off on BioRestorative Therapies Announces the Appointment of Harvard Medical School's Wayne Marasco, M.D., Ph.D., as Chairman …

Stem Cell Therapy—Breakthrough in Health Paradigm

Posted: Published on September 26th, 2012

By Sharmistha Banerjee - September 25, 2012 | Tickers: NBS, OSIR, PSTI | 0 Comments Sharmistha is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. Far-reaching accomplishments in the biotechnology sector meet its most ambitious expectations, stem cell therapy. The birth of this new industry has boosted the enthusiasm and energy of investors and has brought unprecedented capability and optimistic predictions. New developments in regenerative medicine are bringing about exciting, novel approaches to create therapies for hard to treat diseases. The biotechnology industry has been soaring in 2012 as companies both large and small have shown impressive growth. The cell therapy space has seen relatively small companies making strides in the right direction with increased government support. Osiris Therapeutics (NASDAQ: OSIR) a leading stem cell company is currently the only company with an approved cell therapy. The approval is more of a first step in a long walk for Osiris. Reuters reported that shares of Osiris Therapeutics rose 15% on May 30, 2012, after U.S. health regulators said the stem cell technology company's wound treatment was eligible for reimbursement when used in hospitals in out-patient settings … Continue reading

Comments Off on Stem Cell Therapy—Breakthrough in Health Paradigm

CHMP in Favor of Lilly's Cialis

Posted: Published on September 26th, 2012

Eli Lilly and Companys (LLY) Cialis (tadalafil) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (:EMA). The CHMP issued an opinion in favor of approving Eli Lillys erectile dysfunction (ED) drug, Cialis (5 mg), for the once-daily treatment of the signs and symptoms of benign prostatic hyperplasia (:BPH). A response from the European Commission regarding Cialis regulatory status should be out in two months. The CHMPs opinion was based on a review of safety and efficacy data on 1,500 patients from four clinical studies of BPH, including a study of BPH and ED. Cialis label expansion would provide patients suffering from both ED and BPH with a new treatment option. Approval for the additional indication will help boost Cialis sales, which came in at $1.9 billion in 2011. Cialis, which is approved for the treatment of ED in the EU, is approved for the treatment of ED as well as the treatment of BPH in the US. Cialis main competitors in the ED market include Pfizers (PFE) Viagra and GlaxoSmithKlines (GSK) Levitra. The BPH market is also pretty crowded with products like Glaxo's Avodart and Jalyn, Sanofis (SNY) … Continue reading

Posted in Erectile Dysfunction | Comments Off on CHMP in Favor of Lilly's Cialis

Stem cells revolutionizing veterinary medicine

Posted: Published on September 26th, 2012

(WGBA/NBC) - It is a story that gives hope to pet owners all over the country stem cell therapy for animals suffering from problems like arthritis or hip displaysia. Stem cells are taken out of the dog's fatty tissue are harvested then injected into problem areas leaving the dogs completely healed. "We couldn't take him on walks, he just laid around a lot," said Keith Nosowiak, Deniro's owner. "We'd hear whimpering overnight, she'd take a few steps and she would sit down," said Luther Kortbein, Shadow's owner. Until two months ago, Deniro suffered from severe arthritis, Shadow from hip displaysia. Deniro's owner thought he may even have to put his German shepherd down. "We felt we had a decision to make with his quality of life and being in pain we didn't want him to be in pain," Noskowiak said. Shadow's owner was willing to try anything to cure her. "Whatever the cost needed to get this done we were willing to do," Kortbein said. Then Packerland Veterinary Center offered them stem cell therapy by using the dogs own stem cells and then injecting them back into the bloodstream joints. See more here: Stem cells revolutionizing veterinary medicine … Continue reading

Posted in Pet Stem Cell Therapy | Comments Off on Stem cells revolutionizing veterinary medicine

Pacemaker from Stem Cells Receives Research Funding

Posted: Published on September 26th, 2012

(SACRAMENTO, Calif.) - Deborah K. Lieu, a stem cell scientist in cardiovascular medicine at UC Davis Health System, has received a $1.3 million research grant from the California Institute for Regenerative Medicine (CIRM) to develop stem cells that could serve as a biological alternative to the electronic pacemakers that people now use to regulate heart rhythm. According to Lieu, each year 350,000 cardiology patients with abnormal heart rhythms receive electronic pacemakers to maintain a normal heart beat. The devices, while effective, have several disadvantages, including limited battery life and poor response to changing heart rates, such as when a person is exercising. Lieu, who is working with colleague Nipavan Chiamvimonvat, the Roger Tatarian Endowed Professor of Cardiovascular Medicine at UC Davis, plans to examine ways to improve the generation of pacemaking cells using human-induced pluripotent stem cells (hiPSCs), potentially creating what she calls a "biopacemaker." "There are more than 3 million patients around the country who are dependent on electronic pacemakers," said Lieu. "Each one costs about $58,000 to implant and requires follow-up surgery about every 5 to 10 years to change batteries. Creating a biopacemaker from stem cells would avoid the burden of battery replacement and provide the physiological … Continue reading

Posted in Cell Medicine | Comments Off on Pacemaker from Stem Cells Receives Research Funding

With this wonder drug, you just pop till you drop

Posted: Published on September 26th, 2012

Back at home, I googled the drug to find that these are: depression, sleeping difficulties, nausea, insomnia, a potentially dangerous increase in heart rate, feelings of hostility, suicidal thoughts and nightmares. Other than that, it sounds like a real life-enhancer. If my husband had fathered a love-child with our housekeeper (its not impossible shes an attractive woman, and the way she vacuums borders on indecent), I think Id like to know before a marriage therapist. Id see that as the bare minimum in terms of respect, really. Because to find out at the same time as some bespectacled, 100-quid-an-hour outsider well, that might be a little humiliating. Apparently, Maria Shriver doesnt share my viewpoint. In his new memoir, Arnold Schwarzenegger says that he was forced to come clean about his love-child with his housekeeper, Mildred Baena, by his wife during their couples counselling session. The minute we sat down, he writes, the therapist turned to me and said, 'Maria wanted to come here today and to ask about a child whether you fathered a child with your housekeeper. Now, Im sure marriage therapy works for some, but this kind of interventionism just reminds me of playing the invisible sibling game … Continue reading

Posted in Drug Side Effects | Comments Off on With this wonder drug, you just pop till you drop

Page 6,424«..1020..6,4236,4246,4256,426..6,4306,440..»